Kenvue IncNYSE: KVUE
Consumer Staples · Personal Care Products
$18.24
+1.25%
Vol: 7.1M
Research Digest
Thursday, June 18, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Kenvue Q1 beats; Annual Meeting May 21 amid Kimberly-Clark mergerNeutral▶
Q1 2026 net sales $3.82-3.91B (+3-4.5% YoY), net income $474M, adj EPS $0.48 matching guidance. Skin Health & Beauty (Neutrogena, Aveeno) drove growth. No earnings call due to pending Kimberly-Clark transaction. FY26 guide reaffirmed: 2.5-4.0% revenue growth, adj EPS $1.85-$1.95. Dividend $0.21 paid May 27. Annual Meeting May 21, 2026. Analysts skeptical on KMB merger value; PTs around $19-20.
May 20No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 19Kenvue (KVUE) stock highlighted as institutional-flow tactical indicator on May 17 as Kimberly-Clark merger approaches mid-2026 close.Neutral▶
On May 17, 2026, KVUE was featured by Stock Traders Daily as a liquidity-pulse indicator for institutional positioning ahead of the pending Kimberly-Clark merger, which both shareholder bases approved in January 2026 and is targeted for completion in H2 2026. Recent fundamentals (Q1 net sales +4.5%, EPS $0.25 +47% YoY) and a $0.21 May 13 ex-dividend reinforce the steady-state thesis until deal close. This matters because pre-close arb spreads and event risk dominate near-term KVUE price action. Bear case: regulatory delays or deal-term renegotiation could break the merger narrative; pet-/consumer-staples demand remains soft.
May 18Kenvue beat Q1 estimates with adjusted EPS of $0.48 as Kimberly-Clark merger progresses, with General Counsel exiting stake.Mixed▶
Kenvue's General Counsel Matthew Orlando sold 38,491 shares of common stock in an open-market transaction on May 8, 2026 at a weighted-average price of $17.66 per share, fully exiting his stake. The Q1 2026 results reported May 7 showed sales of $3.82 billion (up 3.1% YoY), with adjusted EPS of $0.48 beating the consensus of $0.26-$0.32. Skin Health & Beauty (Neutrogena, Aveeno) drove growth, and full-year 2026 guidance remains anchored at revenue growth of 2.5%-4.0% and adjusted EPS of $1.85-$1.95. The pending $48.7 billion acquisition by Kimberly-Clark continues to progress, with Kenvue forgoing its quarterly conference call. A quarterly dividend of $0.2075 per share was paid May 27, 2026. Analysts upgraded the stock, citing stronger consumer health portfolio performance, with implied fair value around $19.75.
May 15Kenvue General Counsel Matthew Orlando sold 38,491 shares May 8 exiting his entire direct stake, as the pending $40B Kimberly-Clark acquisition advances with US antitrust approval and is on track to close 2H 2026.Mixed▶
Kenvue reported Q1 2026 sales of $3.91B (up 4.5%) with organic sales up 0.7% and diluted EPS of $0.25, up from $0.17 prior year. Gross margin expanded to 58.9% (adjusted 60.8%), operating margin rose to 19.6% (adjusted 24.0%). Board declared a $0.2075 quarterly dividend payable May 27 to holders of record May 13. The Kimberly-Clark acquisition has received shareholder and major US antitrust approvals, on track to close in 2H 2026. On May 8, GC Matthew Orlando sold 38,491 shares in open-market sale, leaving zero directly owned KVUE common stock. J.P. Morgan upgraded to Buy with $32.50 PT on May 5. Risk: deal break premium evaporates if regulatory approval stalls; insider exit raises optical concern.
May 14Kenvue reports Q1 2026 sales of $3.91B and net income of $474M ahead of Kimberly-Clark merger close, with BofA upgrading to Buy at $32.50 target.Positive▶
Kenvue reported Q1 2026 results on May 7 with sales of $3.91B (up 4.5% YoY, organic growth +0.7%, FX +3.8%) and net income of $474M ($0.25 EPS from continuing operations). Gross margin improved to 58.9% from 58.0%, and free cash flow rose to $0.4B from $0.2B. The pending merger with Kimberly-Clark, announced November 2, 2025, was approved by both companies' shareholders on January 29, 2026, with Kimberly-Clark acquiring all outstanding Kenvue shares in a cash-and-stock deal. The Board approved a restructuring program on February 17 expected to incur about $250M in pre-tax charges in fiscal 2026. BofA upgraded to Buy with a $32.50 target on May 5, joined Zacks Strong Buy list. Stock trading around $17.43.
May 13Kenvue's General Counsel sold 38,491 shares on May 8 as the company progresses toward its $48.7B acquisition by Kimberly-Clark expected to close in H2 2026.Mixed▶
Kenvue General Counsel Matthew Orlando sold 38,491 shares on May 8, 2026, at an average price of $17.66. The company recently reported Q1 2026 results: $0.32 EPS beating the $0.27 consensus, and revenue of $3.91 billion (+4.5% YoY) above the $3.84 billion estimate, with gross margin expanding to 58.9%. Kenvue continues to progress toward closing its $48.7 billion definitive merger with Kimberly-Clark, which shareholders approved in late January 2026 and which is expected to close in the second half of 2026. The board approved a 2026 Restructuring Initiative with ~$250 million in pre-tax charges to optimize the operating model and supply chain. A separate analyst upgrade on May 5 raised KVUE's rating from Hold to Buy with a $32.50 price target. A $0.2075 dividend is payable May 27.
May 12Kenvue rallies on Q1 EPS beat and Buy upgrade as Kimberly-Clark merger approval clearance progressesPositive▶
Kenvue beat Q1 2026 estimates with $0.32 EPS, 4.5% sales growth, and strong margin expansion (+47% EPS YoY). Self Care sales rose 1.9%, Skin Health and Beauty up 8.4%, and Essential Health up 4.9%. Shares traded at $28.40 on May 7, up 4.2% over five sessions following analyst upgrades. A May 5 upgrade lifted KVUE from Hold to Buy with $32.50 target, while Bank of America rates Buy at $31. Forward guidance withheld due to pending Kimberly-Clark $48.7B acquisition, which received shareholder approvals and U.S. antitrust clearance, expected to close H2 2026. Quarterly dividend of $0.21 goes ex May 13.
May 11Kenvue posted Q1 EPS beat of $0.32 (19.9% surprise) with JPMorgan upgrade to Buy at $32.50 target ahead of pending Kimberly-Clark merger closePositive▶
Kenvue reported Q1 2026 results on May 7 with adjusted EPS of $0.32, a 19.9% beat versus estimates, and revenue of $3.78 billion (net sales up 4.5%, organic growth 0.7%, FX benefit 3.8%). Gross margin expanded to 58.9% from 58.0%. Free cash flow doubled YoY to $0.4 billion. No earnings call was held due to the pending $48.7 billion Kimberly-Clark acquisition approved by shareholders in January 2026. The 2026 Restructuring Initiative is projected to cost ~$250 million pre-tax. JPMorgan upgraded KVUE to Buy on May 5 with a $32.50 price target. BofA upgraded to Buy at $31 in early April. KVUE declared a $0.207 dividend with ex-date May 13.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| PGPROCTER | $151.29 | +0.48% | +6.5% | 21.2x | 0.39 | $350.6B |
| KVUEKENVUE | $18.24 | +1.25% | +5.0% | 14.6x | 0.50 | $34.6B |
| ELESTEE | $84.08 | +1.96% | +8.3% | 25.9x | 1.25 | $29.8B |
| WMTWALMART | $117.25 | -0.74% | -12.0% | 35.9x | 0.60 | $940.1B |
| COSTCOSTCO | $952.74 | -1.33% | -11.8% | 42.7x | 0.87 | $428.2B |
| KOCOCA | $78.99 | -1.18% | -2.4% | 22.9x | 0.35 | $343.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.